BLUEBERRIES MEDICAL CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.015 CAD | -25.00% |
|
0.00% | -25.00% |
| 2023 | Blueberries Medical Corp. announced that it has received CAD 1.987876 million in funding | CI |
| 2023 | Blueberries Medical Corp. announced that it expects to receive CAD 1.987876 million in funding | CI |
| Sales 2021 | 0.14 0.19 | Sales 2022 | 0.24 0.32 | Capitalization | 4.37M 6.01M |
|---|---|---|---|---|---|
| Net income 2021 | -5M -6.88M | Net income 2022 | -1M -1.38M | EV / Sales 2021 | 83,334,559 x |
| Net Debt 2021 | 95.7K 132K | Net cash position 2022 | 76.33K 105K | EV / Sales 2022 | 18,219,899 x |
| P/E ratio 2021 |
-2.02
x | P/E ratio 2022 |
-2.3
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 40.21% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -25.00% | ||
| Current month | -25.00% | ||
| 1 month | -25.00% | ||
| 3 months | -50.00% | ||
| 6 months | -25.00% | ||
| Current year | -25.00% |
1 month
0.00
0.03
Current year
0.000.04
1 year
0.000.04
3 years
0.000.14
5 years
0.000.84
10 years
0.000.88
| Managers | Title | Age | Since |
|---|---|---|---|
Facundo Garretón
CEO | Chief Executive Officer | - | 21-01-19 |
| Director of Finance/CFO | - | 21-05-31 | |
| Corporate Officer/Principal | - | 21-02-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Facundo Garretón
CEO | Chief Executive Officer | - | 21-01-19 |
| Director/Board Member | - | - | |
| Director/Board Member | 49 | - |
| Date | Price | Change | Volume |
|---|
Delayed Quote Canadian Securities Exchange, April 16, 2024 at 02:37 pm EDT
More quotes
Blueberries Medical Corp. is a Canada-based company, which is a licensed producer of psychoactive and non-psychoactive cannabis by-products in Colombia. The Company is engaged in the growth, cultivation, and development of medicinal cannabis and related products with operations in Colombia. The Company is focused on processing and supplying medicinal-grade Cannabis oil extracts, medical flowers, and related products. It is developing and commercializing a range of cannabis-derived ingredients, including high and low tetrahydrocannabinol (THC), cannabidiol (CBD), and other cannabinoids. The Companyâs subsidiaries include Blueberries Research Corporation (BRC), Blueberries SAS (BBSAS), Centro De Desarrollo e Investigacion (CDIBBSAS), BBV Labs Inc. (BBV Labs.) and SATIN S.A.S. (SATIN). Blueberries SAS is a licensed producer and distributor of medicinal Cannabis and Cannabis-derived products in Colombia.
Sector
Drug Retailers
Calendar
2024-04-30
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -25.00% | 4.34M | |
| +22.33% | 3.12B | |
| +25.85% | 1.84B | |
| +88.16% | 635M | |
| +13.18% | 525M | |
| +45.07% | 178M | |
| +10.03% | 105M | |
| -2.22% | 102M | |
| +79.78% | 66.44M |
- Stock Market
- Equities
- BBM Stock
